Repeated ketamine infusions for antidepressant-resistant PTSD: Methods of a multicenter, randomized, placebo-controlled clinical trial

Posttraumatic stress disorder (PTSD) is a debilitating disorder with limited medication treatment options. Recent reports have described the dearth of research on new drug development as a crisis in the pharmacotherapy of PTSD. There are only two PTSD medications approved by the U.S. Food and Drug Administration, and both are serotonergic antidepressants. Therefore, there is a tremendous need to identify more effective and more rapidly acting pharmacotherapies for PTSD that work through novel neural mechanisms.

Source: Contemporary Clinical Trials - April 14, 2019 Category: Radiology Authors: Chadi G. Abdallah, John D. Roache, Lynnette A. Averill, Stacey Young-McCaughan, Brenda Martini, Ralitza Gueorguieva, Timothy Amoroso, Steven M. Southwick, Kevin Guthmiller, Argelio L. L ópez-Roca, Karl Lautenschlager, Jim Mintz, Brett T. Litz, Douglas E. Source Type: research